Table 1 Baseline characteristics of the study population
|  | N = 47 |
|---|---|
Age | 61 (39–73) |
Gender (male/female) | 28/19 |
Smoking history | 33 (70.2%) |
ECOG Performance Status | 31/16 |
 0 | 31 (66.0%) |
 1 | 16 (34.0%) |
Histology | |
 adenocarcinoma | 47 (100%) |
Staging | |
 IIIB | 5 (10.6%) |
 IV | 39 (83.0%) |
 recurrent | 3 (6.4%) |
EGFR mutation | |
 wild type | 32 (68.1%) |
 exon19 deletion | 7 (15.2%) |
 exon21 L858R | 5 (10.9%) |
 exon21 L858R + de novo T790 M | 1 (2.1%) |
 unknown | 2 (4.2%) |
Prior treatment | |
 surgery | 3 (6.4%) |
 palliative radiotherapy | 3 (6.4%) |
 EGFR tyrosine kinase inhibitor | 0 |